A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
Zoetis Inc. is a global leader in the animal health industry, focused on the discovery, development, manufacture and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests and precision animal health. We have a diversified business, commercializing products across eight core species: dogs, cats and horses (collectively, companion animals) and cattle, swine, poultry, fish and sheep (collectively, livestock); and within seven major product categories: parasiticides, vaccines, dermatology, anti-infectives, pain and sedation, other pharmaceutical and animal health diagnostics. With a legacy of nearly 75 years, we continue to pioneer ways to predict, prevent, detect, and treat animal illness, supporting those raising and caring for animals worldwide - from veterinarians and pet owners to livestock producers. We were incorporated in Delaware in July 2012 and prior to that the company was a business unit of Pfizer Inc. (Pfizer).
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 9.5B | 9.5B | 9.3B | 8.5B | 8.1B | 7.8B |
| Net Income | 2.7B | 2.7B | 2.5B | 2.3B | 2.1B | 2.0B |
| EPS | $6.02 | $6.02 | $5.47 | $5.07 | $4.49 | $4.27 |
| Free Cash Flow | 2.3B | 2.3B | 2.3B | 1.6B | 1.3B | 1.7B |
| ROIC | 27.8% | 27.2% | 24.5% | 26.1% | 25.7% | 28.5% |
| Gross Margin | 71.8% | 71.8% | 70.6% | 70.0% | 69.6% | 70.4% |
| Debt/Equity | 2.77 | 2.77 | 1.70 | 1.35 | 1.84 | 1.48 |
| Dividends/Share | $2.00 | $2.03 | $1.80 | $1.56 | $1.35 | $1.08 |
| Operating Income | 3.6B | 3.6B | 3.3B | 3.2B | 2.9B | 2.7B |
| Operating Margin | 37.8% | 37.8% | 36.2% | 37.2% | 35.6% | 34.9% |
| ROE | 80.2% | 66.0% | 52.1% | 46.9% | 48.0% | 44.8% |
| Shares Outstanding | 444M | 444M | 454M | 462M | 471M | 477M |
Zoetis Inc. passes 8 of 9 quality checks, indicating strong fundamentals.
Zoetis Inc. trades at 19.9x trailing earnings, compared to its 15-year median P/E of 34.4x, suggesting it is currently Cheap relative to its historical range. On a free-cash-flow basis, the stock trades at 22.2x vs a median of 44.9x. The company's 5-year average ROIC is 26.4% with a gross margin of 70.5%. Total shareholder yield (dividends + buybacks) is 7.7%. At current prices, the estimated annualized return to fair value is +7.7%.
Zoetis Inc. (ZTS) has a current P/E ratio of 19.9, compared to its historical median P/E of 34.4. The stock is currently considered Cheap based on its historical valuation range.
Zoetis Inc. (ZTS) has a 5-year average return on invested capital (ROIC) of 26.4%. This indicates strong capital allocation and a potential competitive advantage.
Zoetis Inc. (ZTS) has a market capitalization of $53.3B. It is classified as a large-cap stock.
Yes, Zoetis Inc. (ZTS) pays a dividend with a trailing twelve-month yield of 1.67%. The company also returns capital through share buybacks, with a buyback yield of 6.07%.
Based on historical P/E analysis, Zoetis Inc. (ZTS) appears cheap. The current P/E of 19.9 is 42% below its historical median of 34.4. The estimated fair value CAGR (P/E method) is 12.0%.
Zoetis Inc. (ZTS) operates in the Pharmaceutical Preparations industry, within the Healthcare sector.
Zoetis Inc. (ZTS) reported annual revenue of $9.5 billion in its most recent fiscal year, based on SEC EDGAR filings.
Zoetis Inc. (ZTS) has a net profit margin of 28.2%. This is a strong margin indicating high profitability.
Zoetis Inc. (ZTS) generated $2.3 billion in free cash flow in its most recent fiscal year. Positive free cash flow supports dividends, buybacks, and debt reduction.
Zoetis Inc. (ZTS) has a debt-to-equity ratio of 2.77. This indicates higher leverage, which may increase financial risk.
Zoetis Inc. (ZTS) reported earnings per share (EPS) of $6.02 in its most recent fiscal year.
Zoetis Inc. (ZTS) has a return on equity (ROE) of 66.0%. This indicates the company generates strong returns for shareholders.
Zoetis Inc. (ZTS) has a 5-year average gross margin of 70.5%. This high margin suggests strong pricing power and a potential competitive moat.
The Ledger Terminal provides 15 years of financial data for Zoetis Inc. (ZTS), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
Zoetis Inc. (ZTS) has a book value per share of $7.50, based on its most recent annual SEC filing.